GlassScriptPhysician profile
Khaled Abdulla
NPI 1811423684
$2,577.28
in general payments reported to CMS, 2019-2025
24 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $440 · 2022: $494 · 2023: $232 · 2024: $374 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $480.79 | 2021-2025 | |
| Amgen INC. | $336.80 | 2022-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $318.17 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $292.79 | 2023-2025 | Watchman Flx, General - Therapies |
| Pfizer INC. | $174.43 | 2022-2025 | |
| Cvrx, INC. | $129.09 | 2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $123.44 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $115.61 | 2023-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $108.90 | 2024-2025 | Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $66.01 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $48.72 | 2024-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $44.21 | 2021-2025 | Farxiga, Lokelma |
| Actelion Pharmaceuticals US, INC. | $43.08 | 2024-2025 | Opsumit, Uptravi |
| Novo Nordisk INC | $40.10 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $37.88 | 2024 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $33.84 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.37 | 2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $27.21 | 2025 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $24.34 | 2024 | Evkeeza |
| Becton, Dickinson and Company | $23.55 | 2024 | |
| Glaxosmithkline, LLC. | $23.01 | 2025 | Shingrix, Arexvy |
| Medtronic, INC. | $20.64 | 2024 | Cobalt Dr Mri Surescan |
| Lantheus Medical Imaging, INC. | $17.80 | 2023 | Definity |
| Livanova USA, INC. | $14.50 | 2023 | Lifesparc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Abdulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.